Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24076553&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Angiogenic factors in preeclampsia: potential for diagnosis and treatment #MMPMID24076553
Goel A; Rana S
Curr Opin Nephrol Hypertens 2013[Nov]; 22 (6): 643-50 PMID24076553show ga
PURPOSE OF REVIEW: The review summarizes new observations of key roles for circulating angiogenic factors in diagnosing, managing, and treating preeclampsia. RECENT FINDINGS: Alterations in circulating angiogenic factors (soluble fms-like tyrosine kinase-1 and placental growth factor) in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). Measurement of these angiogenic biomarkers further helps differentiate preeclampsia and its complications from other disorders that present with similar clinical profiles. A ratio of soluble fms-like tyrosine kinase-1/placental growth factor greater than 85 appears ideal as the cut-off for both diagnosis and prognosis. There is also evidence that modulating these factors has therapeutic effects, suggesting a future role for angiogenic factors in treatment and prevention of preeclampsia. SUMMARY: Circulating angiogenic biomarkers help in diagnostic and prognostic profiling of preeclampsia and may facilitate better management of these patients.
free
free
free
Curr+Opin+Nephrol+Hypertens 2013 ; 22 (6): 643-50
